National Institute for Clinical Excellence Publishes Medical Innovation Briefing Appraising QbTest

Globally recognized Health Technology Assessment Body recognizes benefits of objective ADHD testing technology from Qbtech

HOUSTON–(BUSINESS WIRE)–The National Institute for Clinical Excellence (NICE), a UK government-funded, non-departmental public body that aims to establish guidelines for clinical best practice, recognizes QbTest in its MedTech Innovation Briefing, MIB318. The Medical Innovation Briefing highlights the benefits of Qbtech�s objective testing technology when used as part of a comprehensive ADHD assessment.

NICE regularly publishes Medical Innovation Briefings to evaluate medical and health technologies for potential use by the National Health Service in the UK. An expert panel is appointed to review technologies for evidence that would benefit clinical practice. The MIB318 covers the clinical value and impact of QbTest, and findings include:

• Experts recognize QbTest as an addition to routine clinical assessment of ADHD
• The NICE evidence review and ADHD experts confirm that QbTest helps clinicians make accurate decisions, saving time and money
• NICE reports reduced ADHD waiting list and prescription costs achieved through QbTest

“We are very pleased to share this news regarding the viability of QbTest,” said Dr Venkat Reddy, Neurodevelopmental Pediatrician, National Clinical Advisor – Focus ADHD Programme, and Officer for Digital Health and Technology, Royal College of Paediatrics and Child Health, “This report reflects the efforts of both Qbtech and all involved in assessing this technology. All our experts agreed that QbTest’s benefits create more efficiency in the pathway to care.”

QbTest is currently used as part of Focus ADHD, an award-winning, NHS-backed program in partnership with Qbtech and the AHSN Network. This program implements objective testing as a standard of care to improve the diagnostic process. The findings from NICE encourage further adoption of objective testing as part of the standard of care for ADHD.

“Receiving praise from the NICE MIB report is a testament to the entire Qbtech team and the tangible benefits of our objective testing technology,” says Tony Doyle, Commercial Director, Qbtech. “When used in conjunction with other clinical measures, QbTest is the ‘gold standard’ to create a more effective and efficient diagnostic and treatment process. We hope this report encourages further adoption of objective testing in clinical practice in the UK, the USA and across our territories globally.”

In addition to its diagnostic application, QbTest was reviewed for its efficacy in treatment monitoring. The MIB states “clinicians found value in the ability to assess medication treatment effects using QbTest” and “clinicians can monitor the effectiveness of a dose of medication to objectively observe its potential impact.”

To learn more about Qbtech and its objective testing measures, visit www.qbtech.com.

About Qbtech

Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the diagnosis, treatment and follow-up of patients living with ADHD. Qbtech has operations in 13 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for their innovation, most recently winning the 2022 HSJ Partnership Award for the ‘Best Mental Health Partnership with the NHS’. www.qbtech.com

Contacts

Hilari Barton, Trevelino/Keller

Hnbarton@trevelinokeller.com
404-214-0722 x 130